Trials / Completed
CompletedNCT00325429
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin |
Timeline
- Start date
- 2006-04-01
- First posted
- 2006-05-12
- Last updated
- 2009-01-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00325429. Inclusion in this directory is not an endorsement.